Hemogenyx Pharmaceuticals Plc (HOPHF)

Market Cap	9.99M
Revenue (ttm)	n/a
Net Income (ttm)	-6.55M
Shares Out	n/a
EPS (ttm)	-2.15
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	25,000
Average Volume	n/a
Open	0.040
Previous Close	0.040
Day's Range	0.040 - 1.240
52-Week Range	0.040 - 16.000
Beta	3.47
RSI	0.00
Earnings Date	Apr 25, 2025

About Hemogenyx Pharmaceuticals

Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood cancer. The company’s lead product candidate is the HEMO-CAR-T therapy for the treatment and potential cure for relapsed and/or refractory acute myeloid leukemia. It also develops chimeric bait receptor to treat COVID-19 virus, as well as to treat brain cancers and/or certain neurodegenerative diseases; and CDX bi-specific antibody which eliminates hematopoietic stem cells/hema...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 17
• Stock Exchange: OTCMKTS
• Ticker Symbol: HOPHF

Financial Performance

Financial numbers in GBP